



TITAN BIOTECH LTD.



AN ISO 9001:2008 CERTIFIED COMPANY

Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subash Place, Delhi-110034, India

Tel. : 011-27355742, 71239900 | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

To,

31-05-2025

BSE Ltd.

Corporate Services Department,

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400001

Sub: Submission of Newspaper advertisement of Audited Financial Results for the quarter and year ended on 31/03/2025 - Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015


Dear Sir/Ma'am,

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in continuation of our letter dated 30/05/2025, please find enclose herewith the copies of the following newspaper advertisements published in viz. Financial Express (English) and Naya India (Hindi) regarding publication of Audited Financial Results of the Company for the quarter and year ended on 31/03/2025. This intimation and Newspaper Copies will also be available on the website of the Company at www.titanbiotechltd.com.

This is for your kind information and record please.

S.N	Name of Newspaper	Publication Date	Language
1	Financial Express	31-05-2025	English
2	Naya India	31-05-2025	Hindi

For Titan Biotech Limited



Charanjit Singh

Company Secretary & Compliance Officer

M. No A12726

R.O. & Works: Unit I: A-902A, RIICO Industrial Aea, Phase III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: hrd@titanbiotechltd.com, accounts@titanbiotechltd.com, purchase@titanbiotechltd.com

Website: www.titanbiotechltd.com | www.tmmedia.in

By Order of Board
Sd/-
Umesh Kumar Modi
Chairman & President
DIN: 00002757

For Vikas Ecotech Limited

For and on behalf of Board of Directors
of Dhanvantri Jeevan Rekha Ltd.
Sd/-
(P.S. Kashyap)
Din: 01664811
Chairman

Notes:

- These financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under.
- The Above result were reviewed by the Audit Committee and approved by the Board of Directors of the Company in their meeting held on 29th May 2025. The Statutory Auditor of the Company have provided Limited Review Report for the same.
- Figures of previous periods were re-grouped/re-classified wherever necessary to confirm to the periods of current periods.
- Indian Accounting Standards are applicable on the Company.
- 1- The Company has reported Segment wise reporting as per Accounting Standard (AS-17). The Company has reported the following Business Segments:
 - Automobile
 - Other
- Complete results are available at Company's website. QR code: 

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is the advertiser's responsibility to verify its contents. The advertiser (or its authorised representative (P)) limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make enquiries, prior to sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED ON 31ST MARCH, 2025						
						(Rs. IN LAKHS) except for EPS
Sr. No.	PARTICULARS	CONSOLIDATED				
		Quarter Ended		Year Ended	Year Ended	Year Ended
		31.03.2025	31.12.2024			
		AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED
1	Total Income from Operations (Net)	266.87	334.90	227.25	1,045.84	739.58
2	Net Profit/(Loss) for the period (before tax, share in profit of associate, exceptional and/or extraordinary items)	(14.07)	95.42	(12.79)	150.59	138.26
3	Net Profit/(Loss) for the period before tax and share in profit of associate (after exceptional and/or extraordinary items)	(14.07)	95.42	(12.79)	150.59	138.26
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	141.21	254.34	154.26	1,047.36	1,006.93
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income(after tax)(refer note 3)	129.22	347.39	85.65	1,263.45	1,055.59
6	Paid-up Equity Share Capital / Face value of Rs. 10/- per share)	2,501.62	2,501.62	2,501.62	2,501.62	2,501.62
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	7,684.12	6,420.68
8	Earning Per Share (of INR 10/- each)					
	(a) Basic	0.56	1.02	0.62	4.19	4.03
	(b) Diluted	0.56	1.02	0.62	4.19	4.03

